Lexaria Bioscience (LEXX) Liabilities from Discontinued Operations (2014 - 2020)
Lexaria Bioscience (LEXX) posted Liabilities from Discontinued Operations of 250.0 for Q3 2020, little changed sequentially from 250.0 in Q2 2020.
Lexaria Bioscience (LEXX) Liabilities from Discontinued Operations (2014 - 2020) Analysis & Trends
Lexaria Bioscience has reported Liabilities from Discontinued Operations for 2 years, with the latest figure at 250.0 in Q3 2020.
- Quarterly Liabilities from Discontinued Operations changed N/A year-over-year to 250.0 in Q3 2020, while the trailing twelve-month figure through Aug 2020 was 250.0 (changed N/A YoY) and the FY2020 annual result came in at 250.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations held at 250.0 in Q3 2020 per LEXX's latest filing, from 250.0 in the prior quarter.
- Over five years, Liabilities from Discontinued Operations peaked at 250.0 in Q2 2020 and troughed at 250.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Aug 31, 2020 | 250.00 |
| Aug 31, 2020 | 250.00 |
| May 31, 2020 | 250.00 |
| May 31, 2020 | 250.00 |
| Nov 30, 2014 | 678,193.00 |
| Nov 30, 2014 | 678,193.00 |